Hosted on MSN29d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — againHims launched in 2017, selling generic hair loss, sexual health, and skincare drugs online via telemedicine. It began selling weight loss copies in 2023.
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...
Going forward, the company said its weight ... Hims & Hers' competitors will likely shift marketing dollars back to other products for conditions such as erectile dysfunction and hair loss ...
Hims & Hers Health said fourth-quarter revenue surged as demand for its weight-loss treatments took ... in its portfolio focus on sexual health, hair loss and mental health, among others.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results